Overview of CIDR

What Is CIDR? Overview

Property	Description
Active Ingredient	Progesterone (Steroid Hormone)
Form	Intravaginal Insert (Silicone Matrix)
Pharmacological Class	Progestogen
Common Use	Estrus (Heat) Synchronization in Livestock
Origin	Synthetic

What Is CIDR and Its Main Ingredient?

CIDR (Controlled Internal Drug Release) is a veterinary drug delivery system designed to control and synchronize the reproductive cycles of female livestock. This unique system is an intravaginal insert whose sole active ingredient is the steroid hormone, progesterone. Progesterone is officially classified as a progestogen, which is the general pharmacological class of compounds that mimic the effects of the naturally occurring hormone. The progesterone used is a synthetic version designed to be structurally identical to the natural hormone. This method of hormonal delivery is clinically recognized for providing a reliable way to manage reproductive timing in herd animals, such as cattle. Progesterone products serve to regulate the reproductive cycle across various species.

The CIDR Insert: Form and Composition

The CIDR insert is a T-shaped device made of a molded silicone matrix, which serves as both the drug reservoir and the dosage form for intravaginal administration. Unlike other drug forms, this insert is defined by its unique physical structure: the active ingredient, progesterone, is uniformly dispersed throughout a flexible silicone material and supported by a nylon spine for secure retention. This composition is essential for its function. The design allows the device to remain safely in place while ensuring the drug is continuously and consistently released directly through the vaginal wall into the bloodstream over the treatment period.

General Purpose of the Controlled Release System

The primary purpose of the CIDR system is to provide a sustained, consistent supply of progesterone, temporarily overriding the animal's natural reproductive cycle. By maintaining a constant, elevated level of this hormone, the device artificially mimics the body's luteal phase (the high-progesterone period after ovulation). This hormonal stability prevents the onset of estrus (heat), which allows herd managers to reliably synchronize the cycles of multiple animals simultaneously. This synchronization is a key tool for improving the efficiency of breeding programs, such as timed artificial insemination (TAI). Intravaginal progesterone inserts are utilized for controlling the estrous cycle.

Regulatory References

What side effects are possible with CIDR?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety restrictions for the veterinary medicine CIDR, strictly based on governmental regulatory documents.

Adverse Reaction Scope

Adverse reactions reported for CIDR in the target species are infrequent and generally related to local effects.

Classification	Adverse Reaction	Description
Frequency	Very Rare (Less than 1 animal per 10,000)	Vaginal discharge and vulva irritation
System-Organ Class	Genital Tract Effects	Local irritation and discharge related to product insertion and removal.

Very Rare Adverse Reactions include vaginal discharge and vulva irritation. The discharge is typically observed at the time the insert is removed and usually resolves before subsequent insemination.

Safety-Related Restrictions and Contraindications

Regulatory documents specify limitations on the use of CIDR to ensure safety and effectiveness. The product must not be used in certain circumstances:

Pregnancy and Calving: Use is contraindicated in pregnant cattle and within the first 35 days after calving due to potential safety risks, which have not been fully established in these conditions.
Genital Conditions: The product must not be used in cows or heifers with abnormal or immature genital tracts or those with pre-existing genital infections.
Single-Use Restriction: To prevent the potential transmission of disease, the insert is restricted to single use only and must never be used more than once.

Safety Summary

The official safety profile is characterized by a low incidence of very rare, local adverse events and strict limitations on use in specific reproductive states and in the presence of existing genital pathology. This structure emphasizes the importance of adherence to use restrictions as defined by regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

The CIDR (Controlled Internal Drug Release) product is a veterinary device; therefore, official regulatory guidance addresses the risk of Accidental Human Exposure to the active ingredient, progesterone. All overdose and emergency-action information is derived strictly from government regulatory documentation concerning this specific scenario.

Documented Manifestations and Actions

Feature	Official Regulatory Guidance
Documented Manifestations	Clinical manifestations of overexposure may include Central Nervous System (CNS) effects such as somnolence (drowsiness), dizziness, and headache. Systemic effects can involve gastrointestinal disturbances and fluid retention.
Antidote Information	No specific antidote is known for progesterone overexposure. Treatment is limited to symptomatic and supportive care.
Immediate Action Required	The official documentation mandates that individuals must call a physician or poison control center immediately if accidental human ingestion or exposure occurs.
Monitoring Requirement	Following exposure, regulatory guidance requires that the exposed person be kept under observation, as the onset of clinical symptoms may be delayed.

All individuals with known or suspected exposure must seek professional medical attention immediately, as documented in the product's official safety profile. Management is based on supportive measures and observation.

Therapeutic Uses of CIDR

What CIDR Treats: Main Uses and Benefits

CIDR is commonly applied to manage the unsynchronized reproductive cycles naturally present across a herd of female livestock. This intervention provides the core therapeutic benefit of establishing controlled, predictable timing for estrus and ovulation. This is relevant in contexts involving anestrus (the absence of heat), delayed postpartum cyclicity, and the need for group synchronization in breeding protocols.

The treatment may assist with increasing the number of eligible breeding animals and is commonly used to help with achieving efficient outcomes in Fixed-Time Artificial Insemination (TAI) and Embryo Transfer programs. The resulting synchronization allows for concentrated breeding and calving seasons, providing supportive relief by assisting with maintaining stability and efficiency during management periods.

“The product is generally used in scenarios that demand enhanced operational control over the breeding calendar for large groups.”

Quick Fact: Support for Unsynchronized Cycles CIDR is applied when symptoms related to systemic imbalance (lack of cycle control) interfere with functional stability. It may assist with managing the functional strain caused by unpredictable breeding readiness.

Regulatory References

DailyMed Labeling for the EAZI-BREED CIDR Cattle Insert

Eligibility and Restrictions for Use

Who Can and Cannot Use CIDR?

The official regulatory profile for CIDR (Progesterone Intravaginal Insert) strictly defines population eligibility based on the reproductive status and health of the target livestock, primarily cattle.

Populations Explicitly Approved and Contraindicated

Eligibility Status	Description (Based on Regulatory Labeling)
Approved Populations	Lactating dairy cows, suckled beef cows, and replacement beef and dairy heifers that are of sufficient size and age for breeding.
Absolute Contraindication	Animals with abnormal, immature, or infected genital tracts. Reuse of the insert is also prohibited.

Eligibility-Related Restrictions

Use is subject to limitations concerning the postpartum interval following calving, as safety and effectiveness have not been demonstrated in all animals immediately after giving birth. The product is not intended for use during pregnancy. Regulatory documents specify that safety and effectiveness are not established in beef cows less than 20 days postpartum and in lactating dairy cows less than 40 days postpartum. Additionally, animals in poor condition due to illness or nutritional stress may not respond to treatment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory profile for the CIDR (progesterone) intravaginal insert is defined primarily by its required co-administration with other hormonal agents as part of approved synchronization protocols, rather than traditional drug-drug interaction conflicts.

Documented Pharmacodynamic Combinations

The official labeling mandates the use of the CIDR insert as a component within a multi-drug hormonal regimen. The documented interactions are essential to the intended functional outcome of the veterinary protocol.

Interacting Substance	Regulatory Status
Dinoprost Tromethamine (Prostaglandin F2alpha analogue)	Required for sequential administration, typically one day prior to CIDR removal, to complete the synchronization protocol.
Gonadorelin (GnRH analogue)	Required as a sequential component of certain approved multi-drug synchronization regimens.

Other Interaction Considerations

The regulatory documentation from various authorities, including the U.S. Food and Drug Administration (FDA) and European agencies, highlights the absence of officially known interactions outside of the required hormonal combinations.

Contraindicated Combinations: No medicinal products are formally classified as a contraindicated combination due to interaction risk.
Pharmacokinetic Interactions: No specific metabolic (e.g., CYP-mediated) or transporter-based interactions are documented in the official regulatory summaries.
Food, Supplements, or Alcohol: No interactions with food, supplements, or alcohol are specified.
Population-Specific Notes: No specific cautions regarding heightened interaction risk in particular animal populations are listed.

Conclusion: The regulatory emphasis is placed on adhering to the specific timing requirements for the necessary sequential co-administration of hormonal components within the authorized regimen.

Mechanism of Action

How CIDR Works: Mechanism of Action

Progesterone Receptor Agonism and Endocrine Mimicry

The core mechanism involves the continuous release of progesterone, which acts as an agonist by binding to its receptors within target cells of the reproductive system. This action establishes a sustained, artificial high-progesterone state that functionally mimics the endocrine signal of a corpus luteum, thereby inhibiting the progression of the estrous cycle.

Central Suppression of the HPG Axis

The high levels of circulating progesterone exert a sustained negative feedback on the hypothalamus and pituitary gland. This central action suppresses the release of key regulatory hormones like Gonadotropin-Releasing Hormone (GnRH) and Luteinizing Hormone (LH), thereby inhibiting the progression of the estrous cycle and preventing the ovulation of a dominant follicle.

Synchronized Systemic Hormonal Reset

Upon removal, the immediate, sharp decline in progesterone concentration relieves the negative feedback on the Hypothalamic-Pituitary-Gonadal (HPG) axis. This sudden hormonal reset triggers a synchronized surge of GnRH and LH, which is the physiological event required to initiate a new estrous cycle shortly thereafter.

Dosage and Administration Information

How to Use CIDR: Official Administration Guidelines

CIDR (Controlled Internal Drug Release) is administered via the intravaginal route as a single-use insert. The device contains 1.38 grams of progesterone, which is released continuously over a defined period. This administration pattern is designed to provide a sustained level of the hormone, consistent with its intended use in reproductive management.

Administration Scope

Feature	Official Instruction
Route of Administration	Intravaginal
Dosing Schedule	Administration of one insert per animal.
Course Duration	The insert is maintained in place for 7 days.
Population	Approved protocols apply to suckled beef cows, replacement beef and dairy heifers, and lactating dairy cows.

Procedural Structure and Restrictions

Proper insertion requires the use of a specialized applicator, which must be washed with a non-irritating antiseptic solution and lubricated before use to facilitate correct placement. The insert is removed exactly seven days after placement to conclude the progesterone administration period.

The device is strictly for single use only. Official instructions prohibit reuse of the insert, which is a mandatory procedural constraint tied to proper handling and disposal.

Connection to the Overall Protocol

These instructions define the standardized, time-bound 7-day course of intravaginal administration for a single device. This structured approach is fundamental because the product is used as a component of a multi-component synchronization regimen that requires the concurrent timing of other hormonal agents to achieve the intended physiological effect.

Recent Clinical Evidence

Research Evidence / Overview of Studies for CIDR

Evidence for Use in Estrus (Heat) Synchronization in Herd Animals

Research involving this intravaginal insert includes a large body of Randomized Controlled Trials (RCTs) and controlled field studies conducted in livestock populations, chiefly beef and dairy cattle. The research explored the device's role as a component within specific hormonal protocols used to manage the timing of the reproductive cycle.

Studies monitored outcomes related to the timing of estrus (heat) and the pregnancy rate observed per breeding event across the groups studied. Findings describe observed patterns related to synchronization efficiency when the device was used according to the specified protocols. However, data show patterns related to environmental factors and animal condition that contribute to heterogeneity in the data reported across different farm settings.

Evidence for Use in Managing Anestrus and Delayed Postpartum Cycles

The insert was studied for its application in female livestock populations experiencing outcomes related to systemic or functional imbalance, such as anestrus (absence of a regular heat cycle) or delayed return to reproductive activity following calving. Studies exploring this use also relied on RCTs and field studies.

Findings describe patterns observed in animals with anestrus or delayed postpartum cycles, with research examining changes measured during the study period, focusing on the animals' return to regular cycling. The evidence contributes to understanding patterns observed in the proportion of animals that entered the breeding cycle after the device was used in specific protocols. What remains uncertain is the influence of non-treatment factors (like nutrition) that often accompany the intervention, and how this variability may be reflected in the results across different research settings.

What Is Still Uncertain and Research Gaps

Research typically focuses on short-term outcomes covering the period of device placement and the subsequent establishment of pregnancy. Consequently, long-term effects are not fully established in the same detail; there is limited information in the core regulatory studies regarding the sustained effects of the protocol on the animals' multi-year productivity.

Comparative evidence is lacking for direct, large-scale comparison against every single alternative synchronization technique available. Additionally, research into new combinations of the device with other hormones is ongoing, meaning that not all evaluated protocols are equally well-characterized by large-scale trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about CIDR (FAQ)

Q: How quickly can someone generally expect CIDR to start working?

Official documents state that the CIDR insert is designed to provide a continuous and consistent release of progesterone immediately upon placement. This continuous supply of the hormone establishes a sustained state that is necessary to suppress the reproductive cycle throughout the required 7-day duration of the treatment.

Q: Are the common side effects of CIDR generally considered mild?

The officially documented adverse reactions associated with CIDR are classified as very rare, meaning they occur in less than 1 animal per 10,000 treated. These events are limited to local effects in the genital tract, such as vaginal discharge and mild vulva irritation, which generally resolve on their own after the insert is removed.

Q: Can CIDR be taken by older adults?

CIDR is a veterinary medicine approved exclusively for the reproductive management of livestock, including suckled beef cows, heifers, and lactating dairy cows. Regulatory guidance is specific to the target animals and does not address the use of this product in humans.

Q: Why might a person need to take CIDR for a long period?

The administration is strictly defined in official instructions as a single insert maintained in place for a structured 7-day course. The device is intended for the temporary management of the estrous cycle in cattle, not for continuous, long-term, or chronic use.

Q: What are the most commonly reported reasons for stopping CIDR?

The administration of the insert is concluded as a mandated part of the synchronization protocol after exactly 7 days. Cessation of treatment due to documented adverse reactions is very rare, and any local effects typically resolve naturally after the device is removed.

Q: Does CIDR make you feel drowsy or affect driving ability?

CIDR is a veterinary product for use in cattle. The officially documented adverse reactions are limited to local genital tract effects in the animal and do not include human-centric systemic effects such as drowsiness or dizziness, which are not relevant to its approved use.

Q: Can women who are planning to become pregnant use CIDR?

CIDR is a veterinary medicine for the reproductive management of livestock (cattle) and is not approved or intended for use by humans, including women planning to become pregnant.

Q: What happens if I miss taking CIDR occasionally?

The product is a single-use intravaginal insert that remains in place for the full 7-day duration. Since it is not a pill or product administered daily, the instruction to 'take a dose' does not apply once the device has been placed according to the authorized procedure.

Q: Is it normal to feel [general symptom like slight dizziness] when starting CIDR?

CIDR is a veterinary product for use in cattle. The officially documented adverse reactions are limited to local genital tract effects in the animal and do not include human-centric systemic effects such as dizziness, which are not relevant to its approved use.

Q: What does official guidance say about CIDR use in children or adolescents?

As a veterinary medicine for specific populations of livestock, official regulatory guidance does not contain information regarding its use in human children or adolescents.

Q: What is the risk of dependence or withdrawal symptoms with CIDR?

The function of the CIDR system is to suppress the reproductive cycle. Official descriptions state that the sharp drop in progesterone upon removal is intended to relieve negative feedback, triggering the physiological hormonal reset needed to initiate a new cycle. Dependence is not a characteristic described in the official product profile.

Q: Why is it important to tell my doctor about all my current medications before starting CIDR?

Regulatory information notes that the insert is used as a component of a multi-component hormonal synchronization regimen for cattle, requiring precise co-administration with other veterinary agents (such as Dinoprost or Gonadorelin) to achieve the intended effect.

Q: Do regulatory bodies list specific groups of people who should not use CIDR?

CIDR is a veterinary medicine, so official regulatory bodies define contraindications for the target animal population (cattle), not for people. Restrictions prohibit use in animals that are pregnant, within specific postpartum intervals, or have abnormal or infected genital tracts.

Q: Is CIDR covered by most health insurance plans?

CIDR is a veterinary medicine for livestock. Official regulatory documentation addresses its safety and efficacy in the product in the target animal population and does not provide information regarding human health insurance coverage.

Q: Can taking CIDR affect my mood or behavior?

Q: What information should I give my pharmacist about CIDR?

CIDR is a veterinary medicine for cattle. Information about its use, contraindications, and protocol timing is typically handled by the veterinarian or a trained animal health professional managing the reproductive protocol.

Q: Does CIDR interact with birth control pills or other hormonal therapies?

CIDR is a veterinary product for cattle. The official regulatory profile describes interactions essential to the veterinary protocol, specifically the required co-administration with other veterinary hormonal agents. No interactions with human hormonal therapies, such as birth control pills, are addressed.

Q: Can I take CIDR if I have an existing allergy to other drugs?

CIDR is a veterinary medicine for cattle and is not approved or intended for human use. Contraindications for the product are specific to the animal's reproductive status and health, such as having an abnormal or infected genital tract.

Q: What is the official patient-reported experience with CIDR?

As a veterinary medicine for livestock, the official safety profile is based on adverse reactions reported to regulatory bodies by veterinarians and handlers. It is not based on subjective human-style patient-reported experience.

Q: How do doctors monitor the need for continued use of CIDR?

The administration schedule is strictly defined as a single 7-day course, after which the insert is removed to trigger the next phase of the protocol. It is not intended for continuous use that would require ongoing monitoring for 'need.'

Q: Can CIDR be used by people with specific dietary restrictions (e.g., gluten-free)?

CIDR is a veterinary medicine for livestock. The regulatory profile addresses interactions related to its use in cattle and does not include information regarding human dietary restrictions, such as gluten content.

Q: What information is published about the use of CIDR in breastfeeding women?

CIDR is a veterinary medicine for cattle. The product is approved for use in the animal equivalent population, specifically lactating dairy cows, as part of their reproductive management protocols.

How should CIDR be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information defines specific rules for storing and disposing of the CIDR (progesterone intravaginal insert).

Storage Conditions

Requirement	Specifics
Temperature	Store at Controlled Room Temperature (CRT), typically between 20 C to 25 C (68 F to 77 F). Do not store above 30 C (86 F).
Protection	Keep in a dry place and out of reach of children. The product must be stored locked up.

Handling and Disposal

The product is for single use only. Handlers should wear protective gloves and wash exposed skin after use. Used inserts must be placed in a sealed container and disposed of according to local, state, and Federal environmental waste regulations. Disposal must avoid release to the environment and prevent the product from entering drains, as the insert contains residual drug substance.

CIDR